Innovation and Product Development news (page 11)

• 

  9 June 2026

  ProLogium and OPmobility to co-develop solid‑state EV battery modules

  Testing of solid‑state cells, module design and aligned test protocols to translate 900 Wh/L cell metrics into OEM‑ready EV modules.
• 

  9 June 2026

  European Commission launches €1.5bn Battery Booster Facility

  Mobilises up to €1.5bn from ETS revenues as interest‑free loans to scale EV battery cell production in the EEA; call opens Q3 2026.
• 

  9 June 2026

  PureCycle & Innovia Films produce white, cavitated BOPP using PureFive Choice™ recycled PP

  White, cavitated BOPP film made with >40% post‑consumer recycled polypropylene showed virgin‑like processing and comparable mechanical, barrier and sealing performance.
• 

  9 June 2026

  Covestro Bayblend T85X R35 CQ (35% PCR PC/ABS) adopted for Lexus ES interiors

  35% post-consumer recycled PC/ABS approved for visible Lexus ES interior parts; material claims 25% lower CO2e GWP vs fossil-based alternatives and was co-developed with Toyota and Kojima.
• 

  9 June 2026

  thyssenkrupp Uhde wins pre‑FEEDs for Fuella’s 2×400 ktpa green ammonia projects in Brazil

  Pre‑FEEDs will optimise concept and integration for two 400 ktpa renewable‑powered ammonia plants at Pecém and Açu, covering electrolysis, balance of plant and ammonia offloading.
• 

  9 June 2026

  GSK to acquire Nuvalent for $10.6 billion

  Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.

• 

  9 June 2026

  Technip Energies, Airbus, Safran and Tereos form Rebound JV to build 160,000 t/y Alcohol‑to‑Jet SAF at Dunkirk

  JV to develop a 160,000 t/y Alcohol‑to‑Jet SAF plant at Port of Dunkirk; partners will fund development, run pre‑FEED/FEED and seek FID after permitting, feedstock and offtake agreements.
• 

  9 June 2026

  PTT Global Chemical positions Map Ta Phut as regional hub for high‑value, low‑carbon businesses with Toray and Mitsubishi

  Turning agricultural residues into bio‑based chemicals; trialled at 50,000‑L fermentation scale; pilot‑scale bio muconic and adipic acid targeted by 2028; pathway to 100% bio‑based nylon 6,6 and expanded market access.
• 

  8 June 2026

  SABIC wins R&D 100 for laser‑weldable NORYL V0 resins

  First‑of‑its‑kind laser‑weldable resins for solar PV enable faster, cleaner microinverter manufacturing with flame retardancy, improved weatherability and lower waste.
• 

  8 June 2026

  Honeywell expands OT Cybersecurity Suite with AI monitoring and secure media controls

  Adds five OT security capabilities — AI monitoring, secure media scanning, data diode, Cyber GRC automation and a managed OT SOC — for manufacturing, energy and critical infrastructure.
• 

  8 June 2026

  Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials

  Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
• 

  8 June 2026

  Gilead and Merck: Phase 3 ISLEND trials show positive topline results for once‑weekly islatravir/lenacapavir

  Once‑weekly oral islatravir 2 mg/lenacapavir 300 mg met Week 48 primary endpoint, non‑inferior to Biktarvy and daily standard‑of‑care; safety profile comparable across arms.
• 

  8 June 2026

  Merck and Gilead discontinue Phase 3 KEYNOTE‑D46/EVOKE‑03 (Trodelvy + KEYTRUDA) in PD‑L1 ≥50% mNSCLC

  eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.
• 

  8 June 2026

  Meccanoplastica showcases INEOS recycled HDPE at PLAST 2026

  Live blow-moulding demo will produce 200ml cosmetic bottles with advanced recycled HDPE; 4L samples use Recycl-IN HDPE with 50% post‑consumer recyclate to support regulatory targets.
• 

  8 June 2026

  Johnson & Johnson to acquire Firefly Bio for $1 billion to add Firelink DAC platform

  Targets KRAS-driven solid tumours with a selective protein degrader; closing expected later this year pending regulatory approvals.
• 

  8 June 2026

  WACKER: ceramifying silicone and 1.6/2.4 W/mK potting compounds for BEV thermal protection

  Ceramifying silicone boosts thermal and flame resistance in battery barriers; potting compounds deliver 1.6 and 2.4 W/mK, low sedimentation and room‑temperature cure.
• 

  8 June 2026

  Siemens and Infineon partner to add CoolSiC SiC modules to SENTRON 3QD2 breakers

  SiC power modules boost semiconductor circuit breakers for faster, denser, more reliable protection in data centers, factories and battery storage.
• 

  8 June 2026

  BASF launches Oppanol® N PLUS binder for next‑generation EV batteries

  High‑spec polyisobutene binder for solid‑state and advanced EV batteries; narrow specs reduce production variability; fresh stock and 20 kg packaging support OEMs.
• 

  8 June 2026

  Roche and Nurix partner to co-develop and co-commercialise BTK degrader bexobrutideg

  Collaboration targets B‑cell malignancies, immunology and neurology with an oral, brain‑penetrant BTK degrader planned for Phase 3 in summer 2026.
• 

  8 June 2026

  AGC Biologics to develop and manufacture KTP-001 (rhMMP-7) for Teikoku Pharma

  Microbial process development and GMP clinical manufacturing of rhMMP‑7 for intradiscal injection; cell bank moved from Heidelberg to Chiba; intended as a lumbar disc herniation treatment.
• 

  7 June 2026

  Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

  Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
• 

  7 June 2026

  Novo Nordisk CagriSema Phase 3 trials show large HbA1c and weight reductions

  Once‑weekly cagrilintide+semaglutide reduced HbA1c by up to 2.33 percentage points and bodyweight by up to 14.2% across REIMAGINE 1–3 versus comparators.
• 

  7 June 2026

  Lilly Foundayo shows weight loss across pre-, peri- and post‑menopause

  Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.
• 

  7 June 2026

  Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup

  VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
• 

  6 June 2026

  Lilly's retatrutide shows major weight loss and benefits for diabetes, knee osteoarthritis and OSA

  Triple agonist produced up to 28.3% weight loss at 80 weeks, A1C fell up to 2.0% at 40 weeks, with large reductions in knee pain and sleep apnea severity.
• 

  6 June 2026

  Novo Nordisk: semaglutide 2 mg escalation matches tirzepatide for HbA1c <7% and yields greater ≥5% weight loss

  Real‑world claims analysis found semaglutide 2 mg escalation gave similar HbA1c <7% rates and higher ≥5% weight‑loss rates than switching to titratable tirzepatide.
• 

  6 June 2026

  Novo Nordisk: semaglutide (Wegovy) post‑hoc data across cardiometabolic conditions

  Post‑hoc analyses link semaglutide to lower OSA incidence, fewer asthma events, improved systolic BP, and liver and cardiometabolic improvements across SELECT, STEP, ESSENCE and OASIS trials.
• 

  5 June 2026

  Röhm opens Bay City MMA plant as LiMA technology reaches full industrial scale

  Proprietary LiMA process reaches full industrial scale; Bay City becomes North America’s first C2‑based MMA site with 250,000 tpa capacity and enhanced sustainability measures.
• 

  5 June 2026

  Novo Nordisk zenagamtide (amycretin) delivers large HbA1c and weight reductions in phase 2 T2D trial

  Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.
• 

  5 June 2026

  Clariant launches Exolit AP 422 A — SVHC‑free ammonium polyphosphate

  New non‑halogenated APP for intumescent coatings, firestop seals and PIR insulation; contains <0.1% melamine to meet REACH SVHC criteria.